Full Fed. Circ. Won't Rethink Decision On Heart Drug IP
The Federal Circuit declined to rethink a decision rejecting Gilead Sciences' and Astellas' argument that they were wrongly barred from responding to amendments Hospira Inc. made to an abbreviated new drug...To view the full article, register now.
Already a subscriber? Click here to view full article